Author

Ernest Michael Meyer

UPMC Hillman Cancer CenterORCID 0009-0003-0984-4410Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:spatial transcriptomics· 2 Approach:deep learning· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Tullia Carmela BrunoiD· 2 shared Aatur Dilip SinghiiD· 1 shared Adam C. SoloffiD· 1 shared Aditi KulkarniiD· 1 shared Anthony Richard CilloiD· 1 shared Anthony Richard GreeniD· 1 shared Armando P. SignoreiD· 1 shared Brian Robert IsettiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Tullia Carmela BrunoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 16, 2026

Integrative multi-omic analysis identifies tumor-intrinsic p38 as a driver of immune exclusion in human epithelial cancers

Rebekah Dadey, Krishna Beer Singh, Rose Doerfler…·Riyue Bao

This study identifies tumor-intrinsic p38 activation as a driver of immune exclusion in epithelial cancers and suggests it as a therapeutic target to overcome immunotherapy resistance.

DOI 10.64898/2026.06.11.731716

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMar 26, 2025

SARC028 samples reveal an interplay between TGF-beta, interferon signaling and low HLA class I expression as contributors to Ewing sarcoma checkpoint blockade resistance

Jessica D. Daley, Elina Mukherjee, David Ferraro…·Kelly M. Bailey

The paper analyzes paired tumor biopsies from Ewing sarcoma patients before and after pembrolizumab therapy to identify features of resistance to checkpoint inhibition.

1 citation

humanspatial transcriptomics

𝕏 PostBluesky